Stock info Novo Nordisk | Filter  Basic-Info

Stock: Novo Nordisk (Danmark large caps), ISIN: DK0060102614

Last Price 453.05 Max Price 1007.00
Min Price 414.30 1 Year return 0.00
Sector Consumer Goods Subsector Personal Goods
Annual report 2015

Loading...

Contact info:Street: Novo AllePostbox: 2880City: BagsvaerdCountry: DenmarkPhone: 45-44-448888Website: www.novonordisk.comCEO: Lars Rebien SoerensenCFO: Jesper Brandgaard

Sector Review Novo Nordisk

Loading...
Year Turnover Total sector Market share
2019 16,338 397,385 4.11 %
2020 17,061 349,402 4.88 %
2021 18,936 443,509 4.27 %
2022 23,802 515,850 4.61 %
2023 31,159 533,922 5.84 %

Advice Novo Nordisk

No Records Found




News Novo Nordisk

Analysts expect record sales Novo Nordisk

Over the current book year the total revenu from the company based in Bagsvaerd will be 208.18 billion Danish Krone (consensus estimates). The expected revenue would be a record for the company. This is quite more than 2022's revenue of 176.95 billion Danish Krone....

Analysts expect over 2018 decreasing revenue Novo Nordisk

Tomorrow the Danish Novo Nordisk will publish its past quarters figures. For this year Novo Nordisk's revenue will be around 111,52 billion Danish Krone. This is according to the average of the analysts' estimates. This is slightly lower than 2017's revenue of111,7...

Novo Nordisk strong outperformer in Denmark

The past years Novo Nordisk gained a lot in value. The past year the 10 year with a huge profit of 384 percent one of the best shares of Denmark. Since the start of this year, the average Danish stock rose year approximately 50 percent in value. Other winners...

Analysts foresee more revenue Novo Nordisk

Next Monday the Danish company Novo Nordisk will publish its past quarter's results. Over the current book year the total revenue will be 112,71 billion euros (consensus estimates). This is slightly more than 2016's revenue of 111,7 billion euros. Historical...

Annual reports Novo Nordisk

2017 2018 2019 2020 2021

Profile Novo Nordisk

Novo Nordisk

(DK0060102614)/ NOVO B

Novo Nordisk has it' headquarter based in Bagsvaerd. Novo Nordisk is mostly active in the personal goods sector. The CEO of Novo Nordisk is Lars Rebien Soerensen. Jesper Brandgaard runs the company as a CFO. Over the past 10 years the global personal goods companies gained around 51 percent. Measured since 2011 the sector is 36 percent higher and over the past 12 months (December 2015-2016) there is a minus of 51 percent.

The past year was a relatively good year for Novo Nordisk investors

Over the period from December 2015 till December 2016 the stock lost around 35 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 97 percent. Novo Nordisk's revenues between 2011 and 2015 were quite unstable and moved between 22,21 billion euros and 38,29 billion euros. Novo Nordisk's net results between 2011 and 2015 were very fluctuating and moved between 17,1 billion euros and 34,86 billion euros.

Over the past 5 years the Danish company paid out dividends. On average the Novo Nordisk stock yielded a delivered a dividend yield of around 22,3 percent over the past 5 years.

At the end of 2015 Novo Nordisk employed at around 40,96 thousand people.

Novo Nordisk' balance mostly financed with equity

Last year the balance sheet of the Danish company was worth 91,8 billion euros. Last year the total debt of the company was 44,83 billion euros. This equals around 48,83 percent of the total balance sheet. The Danish company's price/earnings-ratio was 21. So the market valued the stock at 21 times the 2015' earnings per share. Based on the classical stock valuation theories the Danish stock can be seen as a value stock.

At the end of 2015 the Danish company's market capitalization equaled around 1029,08 billion euros. At the end of 2015 the Danish company had around 2,6 billion stocks listed on the stock exchange(s).

All Novo Nordisk's annual reports can be found here. More information about Novo Nordisk can be found it's website. .


Results Novo Nordisk

Results
2015
2016
2017
2018
2019
2020
Revenue
14,462
15,052
15,007
14,976
16,338
17,061
Costs
9,791
9,946
9,884
9,803
11,123
11,398
Profit
4,671
5,106
5,123
5,173
5,215
5,663
Margin of profit
32.30
33.92
34.14
34.54
31.92
33.19
ROI
74.23
83.77
76.54
74.52
67.63
66.55

Balance Novo Nordisk

Balance
2015
2016
2017
2018
2019
2020
Equity
6,293
6,095
6,693
6,942
7,711
8,510
Debt
6,007
7,039
7,059
7,892
9,108
10,967
Total assets
12,300
13,134
13,752
14,834
16,819
19,477
Solvency
51.16
46.41
48.67
46.80
45.85
43.69
Cash
2,742
2,787
2,533
2,094
2,003
1,626
Cashflow
5,130
6,505
5,531
6,030
6,264
6,982
Employees
40,000
0
0
0
0
Revenue per employee
0.36
0.0
0.0
0.0
0.0
Cashflow / Debt
0.85
0.92
0.78
0.76
0.69
0.64

Details Novo Nordisk

Details
2016
2017
2018
2019
2020
Price
399.90
254.70
334.50
297.90
386.65
Eps
1.00
1.00
1.00
1.00
1.00
Price/earnings-ratio
399.90
254.70
334.50
297.90
453.05
Dividend
0.0
0.0
0.0
0.0
Dividend %
0.00 %
0.00 %
0.00 %
0.00 %
Payout %
0.0
0.0
0.0
0.0
Book value
1.55
1.76
1.87
2.12
2.40
Market to book
0.0
0.01
0.01
0.01
0.01
Cashflow per stock
1.65
1.45
1.62
1.73
1.97
Stocks
3,934
3,813
3,714
3,630
3,551
Market Cap
1.573.124.02
971.203.70
1.242.333.00
1.081.377.00
1.608.780.55

Dividend Novo Nordisk


Price info Novo Nordisk

Date
Price
25 Jun 2025
453.05
20 Jun 2025
488.40
07 Jun 2025
490.35
03 Jun 2025
475.00
28 May 2025
464.85
27 May 2025
460.30
19 May 2025
426.55
09 May 2025
428.90
01 May 2025
435.10
29 Apr 2025
414.30
22 Apr 2025
421.25
09 Apr 2025
434.05
08 Apr 2025
434.05
03 Apr 2025
466.60
30 Mar 2025
474.05
27 Mar 2025
499.80
26 Mar 2025
512.40
20 Mar 2025
544.30
15 Mar 2025
530.20
12 Mar 2025
530.50
01 Mar 2025
644.50
25 Feb 2025
639.20
23 Feb 2025
630.00
18 Feb 2025
569.40
13 Feb 2025
585.70
12 Feb 2025
600.20
07 Feb 2025
628.90
05 Feb 2025
592.60
02 Feb 2025
607.30
21 Jan 2025
551.30